LMATLeMaitre Vascular, Inc.

$80.67-12% 1Y

$80.67

$78.6652 weeks$117.10

Is the price fair?

Fair

The yardsticks disagree: cheap against its own 5-year P/E range (10th percentile) but the cash-flow math implies demanding growth. Treat as fair, not cheap.

1 good, 2 to watch

What the price assumes~+11% a yearderived · Jun 30, 2026

Priced for ~11% a year FCF growth. The price already bakes in strong, sustained growth.

Vs its own P/E rangecheaper than 90% of its own historyderived

Cheap vs its own history: P/E 28.3 vs a 38.3 median over 41 quarters (−26% vs median).

Vs sector (EV/EBIT)26.3×derived · Dec 31, 2025

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)middle of the market

FCF yieldmiddle of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What LMAT's price assumes

LeMaitre Vascular, Inc. trades at 28.3× earnings against 39.6× for the median Medical Instruments & Supplies name, cheaper than its own group.

28.3

Trailing P/E · Medical Instruments & Supplies median 39.6 · cheaper than the typical name in its group

Price / sales: 8.60
Price / sales · today's price, fiscal year to Dec 31, 2025
Free cash flow yield: 3.4%
Free cash flow yield · Medical Instruments & Supplies median 3.4%
Growth the price implies: +11%
Growth the price implies · The price pays for +11% free cash flow growth a year for a decade; the business has delivered +57% a year over the last three.

Details›

Price / booktoday's price, fiscal year to Dec 31, 2025: 5.45
EV / EBITtoday's price, fiscal year to Dec 31, 2025: 26.3
EV / salestoday's price, fiscal year to Dec 31, 2025: 7.16
Healthcare median P/E509 names: 26.2
Medical Instruments & Supplies median P/E33 names: 39.6
Free cash flow, trailing twelve months: $74M
Market capitalisation: $2.15B
3-year free cash flow growth: +57%

What the market has paid for these earnings: 41 quarters of its own multiple × $2.85 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$94.46
Its own P/E history, median	$109.20
Its own P/E history, upper quartile	$122.82
52-week range	$78.66 – $117.10
Today	$80.67

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

Medical Instruments & Supplies

Ranks #2 of 21 by RyuScore

Pulse Biosciences, Inc.

STAA-3.1%

STAAR Surgical Company

BioLife Solutions, Inc.